德美化工(002054.SZ):擬以3000萬元參與設立蘇州天匯納米微球創業投資基金
格隆匯9月29日丨德美化工(002054.SZ)公佈,公司為推進戰略發展,落實公司戰略佈局,公司擬以自有資金3000萬人民幣與江蘇天匯紅優投資管理有限公司(“天匯紅優”)及其他投資方共同發起設立蘇州天匯納米微球創業投資基金(暫定名,以最終工商登記核准為準,“基金”)。
基金規模不少於1.5億元人民幣,各投資方均以貨幣方式出資,該基金投資方向主要為納米微球的上下游關鍵技術和項目,及其應用在診斷、色譜分析、細胞療法、藥物研發與藥物遞送、光電、食品安全檢測、 環保監測等細分領域的優秀早期項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.